Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is not Zepbound and not a generic of it. A compounding pharmacy prepares it, it isn’t FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are sold (FDA, 2026). Zepbound is Eli Lilly’s approved product, with trial results on its label and a self-pay price of $299 to $449 a month with on-time refills. Compounded tirzepatide costs $125 to $399 a month at the 39 programs we rank (each program’s lowest ongoing price), as of October 2026, under rules that have tightened since the shortage ended.

What Zepbound is

Zepbound is a once-weekly tirzepatide injection that acts on two hormone receptors, GIP and GLP-1 (Zepbound prescribing information, rev. 08/2026). The FDA approved it on November 8, 2023 for long-term weight reduction in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes.

Approval means the FDA reviewed Lilly’s own data for this product. In SURMOUNT-1, people lost 15.0% of body weight on average at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, compared with 3.1% on placebo. Those are trial averages, not a promise for any one person.

Zepbound comes as a single-dose pen or vial in six strengths from 2.5 mg to 15 mg, or as a multi-dose vial or KwikPen holding four doses. Like the other GLP-1 drugs, it carries a boxed warning for thyroid C-cell tumors.

What compounded tirzepatide is

A compounded drug is prepared by a pharmacy for a patient’s prescription, outside the FDA approval process. Two kinds of facility are involved with GLP-1s (FDA, 2026-04-01):

• A 503A pharmacy is a state-licensed pharmacy (or a physician) that compounds for an individual patient with a prescription.
• A 503B outsourcing facility may compound from bulk ingredients only if the drug is on the FDA’s 503B bulks list or its shortage list.

Telehealth companies sell compounded tirzepatide inside their own plans. altRx and Contour Health ship it in vials for weekly injection, and some programs sell it as a tablet, such as Strut Health from $199 a month and Willow at $399. Both FDA-approved tirzepatide brands, Zepbound and Mounjaro, are injections, so a tirzepatide tablet is a compounded product.

Zepbound’s label results come from Lilly’s product. They do not transfer automatically to a compounded version the FDA has not reviewed, so you are relying on the pharmacy that made it.

Zepbound vs compounded tirzepatide at a glance

Why the rules changed in 2025

The shortage list mattered because it is one of the two lists that let a 503B facility compound from bulk ingredients. The FDA declared the tirzepatide shortage resolved on October 2, 2024, re-evaluated after a lawsuit, and confirmed it on December 19, 2024. After a court denied a preliminary injunction on March 5, 2025, the FDA said the 503A grace period had ended. The 503B grace period ended March 19, 2025.

Under the FDA’s April 2026 reminder, this is where things stand:

• A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that closely matches a commercially available one: the same active ingredient, in the same, similar or easily substitutable strength, by the same route.
• A prescriber can document a significant difference for a specific patient.
• Adding an ingredient does not automatically get around the rule. The FDA’s example is semaglutide plus B12 at strengths within 10% of the commercial product.
• The FDA does not currently intend to act on compounders that fill 4 or fewer such prescriptions per calendar month.
• Tirzepatide is on neither the 503B bulks list nor the shortage list, so 503B facilities may not use bulk tirzepatide.

On April 30, 2026, the FDA also proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding “no clinical need.” Comments were due June 29, 2026.

How the FDA has enforced it

• September 5, 2025: a “green list” import alert lets GLP-1 ingredients from facilities the FDA has not inspected or evaluated be detained at the border without physical examination (FDA).
• September 2025: more than 50 warning letters went to telehealth companies, concierge practices and medical spas, mostly over claims of sameness with approved drugs (STAT).
• February 6, 2026: the FDA said it intends to restrict GLP-1 ingredients used in compounded drugs mass-marketed as alternatives to approved drugs, and warned of possible seizure and injunction “without further notice” (FDA).
• March 3, 2026: 30 more telehealth companies got letters citing “claims implying sameness with FDA-approved products” (FDA). By March 12, more than 70 had been warned in six months (STAT).

Marketing claims the FDA calls misleading

The FDA’s June 2026 guidance lists these as false or misleading when a telehealth company promotes a compounded drug:

• Branding that implies the telehealth company is the compounder.
• Calling the drug a “generic” of, or “the same as,” an FDA-approved drug.
• Saying it is FDA-approved, or has been evaluated for safety and effectiveness.
• Saying it is clinically proven to give the same result as the approved drug.
• Saying it comes from an “FDA-approved” or “FDA-licensed” pharmacy. The FDA does not approve or license any facility.

What each option costs

On LillyDirect, Zepbound costs $299 a month at 2.5 mg and $399 at 5 mg. Doses from 7.5 mg to 15 mg cost $449 if you refill within 45 days; otherwise 7.5 mg costs $499 and 10 mg to 15 mg cost $699. Vials and the KwikPen cost the same (Lilly), and our vials vs KwikPen guide covers how to order.

Compounded tirzepatide costs $125 to $399 a month at the 39 programs we rank, as of October 2026, taking each program’s lowest ongoing monthly price. A sample, from the cheapest up:

At 10 mg, Zepbound’s $449 with on-time refills is $324 a month more than the cheapest compounded plan we track, though a few compounded plans, such as BMI Doctors’ $470 plan with labs, cost more. Run your own numbers in the GLP-1 cost calculator, or read our compounded tirzepatide cost breakdown.

How to decide

• If your commercial plan covers Zepbound, Lilly’s savings card can bring it to as little as $25 a month. Government beneficiaries are excluded.
• If you have Medicare Part D, the GLP-1 Bridge charges eligible enrollees $50 a month from July 1, 2026 to December 31, 2027, and its prior-authorization form lists the Zepbound KwikPen (CMS).
• If you pay cash and lean toward compounded, ask which pharmacy makes your medication, whether it is 503A or 503B, and what you will pay at higher doses.

Compare plans on our compounded tirzepatide rankings, and make the medical decision with a licensed clinician.

The bottom line

Compounded tirzepatide is not Zepbound, and not a generic of it. A compounding pharmacy prepares it, it isn’t FDA-approved, the FDA has not reviewed it for safety, effectiveness or quality, and its legal footing has narrowed since the shortage ended. Zepbound costs more at higher doses but comes with label trial data and insurance routes. If price decides it for you, read the refund terms before you pay, and use our match tool to see which programs fit you.